Product Name: Besifloxacin Hydrochloride

CAS No.: 405165-61-9
Purity: ≥99%
Shelf Life: 1 year
Storage: Store in a cool, dry place away from light
Brand: Chenxi Pharma
Origin: Jinan, China
Category: API (Active Pharmaceutical Ingredient)

---

Description

Besifloxacin hydrochloride is a next-generation fluoroquinolone antibiotic developed by Bausch & Lomb. Approved by the FDA in May 2009, it is the first fluoroquinolone specifically developed for ophthalmic use. Marketed under the brand name Besivance, it is formulated as a 0.6% ophthalmic suspension for treating bacterial conjunctivitis.

---

Mechanism of Action

Besifloxacin exerts its bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication and cell division. It is effective against a broad spectrum of Gram-positive and Gram-negative pathogens.

---

Clinical Efficacy

Clinical trials involving over 2400 patients demonstrated:

• 80% bacterial eradication rate

• High efficacy in both adults and children (≥1 year)

• Low incidence of adverse effects (<3%), primarily mild ocular symptoms

---

Regulatory & Market Status

• Patented: WO2008091752, US2008176834

• Launched in the USA

• Clinical approval granted in China (June 2010)

---

Keywords: 405165-61-9; Besifloxacin Hydrochloride; Besivance; Fluoroquinolone ophthalmic antibiotic